CANCER VACCINES & ACTIVE IMMUNOTHERAPEUTICS 3RD ANNUAL SUMMIT
Approaches to Optimize Immune Response, Enhance Clinical Development & Drive Commercial Performance
26 – 28 June 2012
Boston, MA
www.cancervaccines-meeting.com
Unlock the potential of your anti-cancer drug.
Dendreon hit all the headlines when Provenge got approval. Then Ipilimumab. And just beneath the surface, a host of others are starting to make waves. With MAGE, PROSTVAC and several other products knocking on the door of market approval, what are you doing to ensure your drug reaches these heights?
Designed by Merck Serono, Immatics Biotechnologies, DCPrime, MedImmune, FDA, Oxford Biomedica and many others, the Cancer Vaccines & Active Immunotherapeutics 3rd Annual Summit will bring together key ...